急性心肌梗死尿激酶与重组链激酶急诊溶栓治疗的临床分析

Clinical analysis of urokinase and recombinant streptokinase emergency thrombolytic therapy in acute myocardial infarction

目的比较尿激酶与重组链激酶溶栓再通率。方法收集2006年1月～2012年12月来我院急诊科就诊符合静脉溶栓要求的AMI病人120例,入院后立即给予静脉溶栓治疗。结果重组链激酶溶栓开通率高于尿激酶,差异有统计学意义。结论重组链激酶比尿激酶更值得在STEA-MI溶栓治疗中临床推广使用。

Objective Compare urokinase and recombinant streptokinase thrombolytic recanalization rate. Methods Collection in January 2006 December 2012 to intravenous Thrombolysis in our emergency department visits in accordance with requirements of 120 patients with AMI, thrombolytic treatment given immediately after admission. Results Recombinant streptokinase in thrombolytic opened than urokinase, differences are statistically significant. Conclusion Recombinant streptokinase is more worthy than urokinase in the stea-mi thrombolytic therapy in clinical use.